GUD:CA:TSX-Knight Therapeutics Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 5.42

Change

+0.01 (+0.18)%

Market Cap

CAD 0.58B

Volume

0.09M

Analyst Target

CAD 8.74
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.01 (-0.09%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.12 (-5.69%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.17 (-7.42%)

CAD 1.61B
CRON:CA Cronos Group Inc

+0.01 (+0.35%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

-0.33 (-2.64%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.28 (-6.78%)

CAD 0.60B
AOV:CA Amotiv Limited

+0.01 (+0.18%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

+0.25 (+3.03%)

CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

+0.08 (+0.55%)

CAD 0.38B
ACB:CA Aurora Cannabis Inc

-0.29 (-4.34%)

CAD 0.36B

ETFs Containing GUD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.50% 36% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.50% 36% F 73% C
Trailing 12 Months  
Capital Gain -4.75% 52% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.75% 48% F 12% F
Trailing 5 Years  
Capital Gain -28.68% 86% B+ 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.68% 86% B+ 13% F
Average Annual (5 Year Horizon)  
Capital Gain -2.62% 55% F 16% F
Dividend Return -2.62% 55% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.03% 100% F 56% F
Risk Adjusted Return -17.46% 45% F 13% F
Market Capitalization 0.58B 74% C 61% D-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector